ES2162198T3 - Agentes estrogenos. - Google Patents

Agentes estrogenos.

Info

Publication number
ES2162198T3
ES2162198T3 ES97302576T ES97302576T ES2162198T3 ES 2162198 T3 ES2162198 T3 ES 2162198T3 ES 97302576 T ES97302576 T ES 97302576T ES 97302576 T ES97302576 T ES 97302576T ES 2162198 T3 ES2162198 T3 ES 2162198T3
Authority
ES
Spain
Prior art keywords
agents
strogen
compounds
fenil
iles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97302576T
Other languages
English (en)
Spanish (es)
Inventor
Chris P Miller
Bach D Tran
Michael D Collini
Arthur Attilio Santilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2162198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2162198T3 publication Critical patent/ES2162198T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES97302576T 1996-04-19 1997-04-15 Agentes estrogenos. Expired - Lifetime ES2162198T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (1)

Publication Number Publication Date
ES2162198T3 true ES2162198T3 (es) 2001-12-16

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97302576T Expired - Lifetime ES2162198T3 (es) 1996-04-19 1997-04-15 Agentes estrogenos.

Country Status (26)

Country Link
EP (1) EP0802183B1 (2)
JP (1) JP4093611B2 (2)
KR (1) KR100480193B1 (2)
CN (1) CN1106383C (2)
AR (1) AR011503A1 (2)
AT (1) ATE206701T1 (2)
AU (1) AU710149B2 (2)
BR (1) BRPI9715334B8 (2)
CO (1) CO4900051A1 (2)
CY (2) CY2325B1 (2)
CZ (1) CZ291701B6 (2)
DE (2) DE69707189T2 (2)
DK (1) DK0802183T3 (2)
EA (1) EA001448B1 (2)
ES (1) ES2162198T3 (2)
FR (1) FR09C0048I2 (2)
HU (1) HU227077B1 (2)
IL (1) IL120701A (2)
LU (1) LU91608I2 (2)
MX (1) MX9702865A (2)
NL (1) NL300416I2 (2)
NO (2) NO309564B1 (2)
NZ (1) NZ314601A (2)
PT (1) PT802183E (2)
SK (1) SK281737B6 (2)
UA (1) UA48148C2 (2)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172100B1 (en) 1997-04-30 2001-01-09 Eli Lilly And Company Antithrombotic agents
US6541499B1 (en) 1997-05-01 2003-04-01 Eli Lilly And Company Antithrombotic agents
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
DE69933212D1 (de) * 1998-05-12 2006-10-26 Wyeth Corp Benzocarbazol und indenoindole derivate als östrogene agentien
ID26890A (id) * 1998-05-15 2001-02-15 American Home Prod 2-fenil-1-(4-(2-aminoetoksi) -benzil)-indol dalam kombinasinya dengan estrogen
CA2331318A1 (en) * 1998-05-15 1999-11-25 James Harrison Pickar Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ES2213984T3 (es) 1998-10-30 2004-09-01 Eli Lilly And Company Derivados de azaindol y su uso como agentes antitrombicos.
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
EP1159268A1 (en) * 1999-03-04 2001-12-05 American Home Products Corporation N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
HK1044777B (en) * 1999-09-13 2006-04-13 Wyeth Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
CN1400904A (zh) * 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
AU2001271782A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
MXPA02012890A (es) * 2000-07-06 2003-10-24 Wyeth Corp Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US20020016318A1 (en) * 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
ATE321754T1 (de) 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
KR20050010886A (ko) * 2002-06-13 2005-01-28 와이어쓰 바제독시펜 치료 방식
ATE433322T1 (de) 2002-07-22 2009-06-15 Lilly Co Eli Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
GT200500080A (es) 2004-04-07 2005-10-31 Polimorfo cristalino de acetato de bazedoxifeno
PE20060676A1 (es) 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
CN1946689A (zh) 2004-04-08 2007-04-11 惠氏公司 作为选择性雌激素受体调节剂的巴西多昔芬抗坏血酸盐
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
MX2007001506A (es) * 2004-08-05 2007-03-27 Wyeth Corp Polimorfo cristalino del clorhidrato de pipindoxifeno monohidratado.
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN101977897A (zh) * 2008-02-11 2011-02-16 惠氏有限责任公司 制备乙酸巴多昔芬的多晶型a的方法
AU2009237657B2 (en) 2008-04-16 2013-04-04 Oasmia Pharmaceutical Ab Novel estrogen receptor ligands
US20120253038A1 (en) * 2009-04-13 2012-10-04 Sandoz Ag Processes for the synthesis of bazedoxifene acetate and intermediates thereof
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
EP2616463A4 (en) 2010-09-14 2014-01-08 Reddys Lab Ltd Dr PREPARATION OF CRYSTALLINE BAZEDOXIFES AND THEIR SALTS
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
US9751835B2 (en) * 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373941A3 (2) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
CA2135160A1 (en) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Indole derivative
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
AU1892097A (en) 1997-10-23
FR09C0048I2 (2) 2010-06-11
CN1170719A (zh) 1998-01-21
CY2325B1 (en) 2003-11-14
DE69707189D1 (de) 2001-11-15
SK47297A3 (en) 1997-11-05
DE69707189T2 (de) 2002-06-20
MX9702865A (es) 1998-05-31
HUP9700777A2 (hu) 1999-06-28
AR011503A1 (es) 2000-08-30
SK281737B6 (sk) 2001-07-10
IL120701A (en) 2005-09-25
NL300416I1 (nl) 2009-12-01
BRPI9715334B8 (pt) 2021-05-25
EA001448B1 (ru) 2001-04-23
NO971815L (no) 1997-10-20
JP4093611B2 (ja) 2008-06-04
IL120701A0 (en) 1997-09-30
AU710149B2 (en) 1999-09-16
NO2009025I2 (no) 2010-11-22
EP0802183B1 (en) 2001-10-10
CO4900051A1 (es) 2000-03-27
NO2009025I1 (no) 2009-11-30
CY2009016I1 (el) 2010-07-28
FR09C0048I1 (2) 2009-06-11
ATE206701T1 (de) 2001-10-15
DK0802183T3 (da) 2002-02-04
EP0802183A1 (en) 1997-10-22
UA48148C2 (uk) 2002-08-15
JPH1036346A (ja) 1998-02-10
PT802183E (pt) 2002-03-28
KR970069037A (ko) 1997-11-07
HU227077B1 (en) 2010-06-28
LU91608I2 (fr) 2009-11-23
CN1106383C (zh) 2003-04-23
HU9700777D0 (en) 1997-06-30
NZ314601A (en) 1999-09-29
HUP9700777A3 (en) 2000-04-28
NO309564B1 (no) 2001-02-19
NL300416I2 (nl) 2010-02-01
CY2009016I2 (el) 2010-07-28
DE122009000061I1 (de) 2009-12-31
NO971815D0 (no) 1997-04-18
BR9715334B1 (pt) 2012-09-04
CZ291701B6 (cs) 2003-05-14
KR100480193B1 (ko) 2005-08-30
HK1002863A1 (en) 1998-09-25
CZ117597A3 (en) 1997-11-12
EA199700044A1 (ru) 1997-12-30

Similar Documents

Publication Publication Date Title
ES2162198T3 (es) Agentes estrogenos.
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
HN1997000090A (es) Compuestos de piridilpirrol
ES2098140T3 (es) Liosferas que contienen gonadotropina.
HN1999000155A (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
HN1997000079A (es) Analogos de indazol sustituido.
HN1997000126A (es) Derivados de indazol
HN1998000036A (es) Compuesto de pirazina
PT877750E (pt) 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
HN1997000023A (es) Derivados de lactama
HN1998000132A (es) Combinaciones terapeuticas
HN1998000124A (es) Terapia de combinacion
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
HN1997000097A (es) Piridinas condensadas con heterociclicos
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1996000101A (es) Terapia combinada para la osteoporosis
BR9811948A (pt) Secretores de hormÈnio do crescimento
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
ES2183340T3 (es) Procedimiento para la preparcion de compuestos de 4-bromometil-bifenilo.
PT1086097E (pt) Compostos sulfonilbenzeno como agentes anti-inflamatorios/analgesicos
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
SE9801494D0 (sv) Novel use
HN1998000199A (es) Agentes terapeuticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 802183

Country of ref document: ES